Abstract
Background: We have developed a novel aqueous polyherbal formulation (SIRB-001) consisting of 3 herbs; Rheum palmatum L., Lonicera Japonica and Rehmannia glutinosa Libosch in the ratio 1:1:3. SIRB-001 has demonstrated efficacious effects in psoriasis patients.
Objective: This study was aimed at scientifically evaluating the in vitro antipsoriatic activity of SIRB-001.
Method: The in vitro anti-psoriatic properties of SIRB-001 were assessed in human keratinocyte cell line; HaCaT. Anti-proliferative effect was studied using MTT assay. Apoptosis was examined by flow cytometry and colorimetric methods. Inflammatory markers and VEGF were determined by ELISA. IL-17/IL-23 secretion was assessed in immune cells. Signaling markers (kinases) by enzymatic assay and Topoisomerase-II activity by Kinetoplast DNA Cleavage assay was tested.
Results: SIRB-001 significantly inhibited (p<0.01) proliferation of HaCaT cells and induced apoptosis. Significant (p<0.01) downregulation of pro-inflammatory markers (TNF- α, IFN-γ, IL-6, NO, sPLA2) and VEGF was observed. IL-17/IL-23 secretion was significantly (p<0.01) alleviated in immune cells (RAW264.7 and THP-1). Inhibition of signaling markers (AKT1, FLT3, MAPK1, PRKCA, MAP2K) was observed. SIRB-001 demonstrated inhibition of Topoisomerase-II activity. High Performance Liquid Chromatography (HPLC) analysis of SIRB-001 was carried out using standard marker compounds chlorogenic acid (tR=13.98min), Acteoside (tR=24.22 min) and Rhein (tR=53.76 min).
Conclusion: The in vitro results substantiate the anti-psoriatic effect of SIRB-001 in patients. SIRB-001 exerted anti-psoriatic effects at cellular level via multiple arms (antiproliferative, pro-apoptotic, anti-inflammatory, anti-angiogenic). This study provides insight into mechanism of action of SIRB-001 and highlights its promising potential for development as a herbal therapeutic agent for psoriasis, emphasizing the need of further pharmacological evaluation and toxicological studies.
Keywords: Apoptosis, herbal, inflammation, keratinocyte, proliferation, psoriasis.
Graphical Abstract
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Evaluation of in vitro Anti-psoriatic Activity of a Novel Polyherbal Formulation by Multiparametric Analysis
Volume: 16 Issue: 2
Author(s): Nadav Shraibom, Alka Madaan*, Vidushi Joshi, Ritu Verma, Anika Chaudhary, Gautam Mishra, Anshumali Awasthi, Anu Taneja Singh and Manu Jaggi
Affiliation:
- Dabur Research Foundation, 22, Site IV, Sahibabad, Ghaziabad, Uttar Pradesh-201010,India
Keywords: Apoptosis, herbal, inflammation, keratinocyte, proliferation, psoriasis.
Abstract: Background: We have developed a novel aqueous polyherbal formulation (SIRB-001) consisting of 3 herbs; Rheum palmatum L., Lonicera Japonica and Rehmannia glutinosa Libosch in the ratio 1:1:3. SIRB-001 has demonstrated efficacious effects in psoriasis patients.
Objective: This study was aimed at scientifically evaluating the in vitro antipsoriatic activity of SIRB-001.
Method: The in vitro anti-psoriatic properties of SIRB-001 were assessed in human keratinocyte cell line; HaCaT. Anti-proliferative effect was studied using MTT assay. Apoptosis was examined by flow cytometry and colorimetric methods. Inflammatory markers and VEGF were determined by ELISA. IL-17/IL-23 secretion was assessed in immune cells. Signaling markers (kinases) by enzymatic assay and Topoisomerase-II activity by Kinetoplast DNA Cleavage assay was tested.
Results: SIRB-001 significantly inhibited (p<0.01) proliferation of HaCaT cells and induced apoptosis. Significant (p<0.01) downregulation of pro-inflammatory markers (TNF- α, IFN-γ, IL-6, NO, sPLA2) and VEGF was observed. IL-17/IL-23 secretion was significantly (p<0.01) alleviated in immune cells (RAW264.7 and THP-1). Inhibition of signaling markers (AKT1, FLT3, MAPK1, PRKCA, MAP2K) was observed. SIRB-001 demonstrated inhibition of Topoisomerase-II activity. High Performance Liquid Chromatography (HPLC) analysis of SIRB-001 was carried out using standard marker compounds chlorogenic acid (tR=13.98min), Acteoside (tR=24.22 min) and Rhein (tR=53.76 min).
Conclusion: The in vitro results substantiate the anti-psoriatic effect of SIRB-001 in patients. SIRB-001 exerted anti-psoriatic effects at cellular level via multiple arms (antiproliferative, pro-apoptotic, anti-inflammatory, anti-angiogenic). This study provides insight into mechanism of action of SIRB-001 and highlights its promising potential for development as a herbal therapeutic agent for psoriasis, emphasizing the need of further pharmacological evaluation and toxicological studies.
Export Options
About this article
Cite this article as:
Shraibom Nadav , Madaan Alka *, Joshi Vidushi , Verma Ritu , Chaudhary Anika , Mishra Gautam , Awasthi Anshumali , Singh Taneja Anu and Jaggi Manu , Evaluation of in vitro Anti-psoriatic Activity of a Novel Polyherbal Formulation by Multiparametric Analysis, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2017; 16 (2) . https://dx.doi.org/10.2174/1871523016666170720160037
DOI https://dx.doi.org/10.2174/1871523016666170720160037 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
System Level Meta-analysis of Microarray Datasets for Elucidation of Diabetes Mellitus Pathobiology
Current Genomics Novel Aspects in the Pathophysiology of Peripheral Vasculopathy in Systemic Sclerosis
Current Rheumatology Reviews To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets Chronic Inflammation and Oxidative Stress as a Major Cause of Age- Related Diseases and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery Molecular-Targeted and Cell-Based Therapies for Sjogren’s Syndrome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Yeast as a Humanized Model Organism for Biotransformation-Related Toxicity
Current Drug Metabolism Mucosal HIV Vaccines: Where are We Now?
Current HIV Research Erratum
Mini-Reviews in Medicinal Chemistry Pt2L4 Protein, a Homologue to Hev b 5 from Rubber Tree, May Not Be Responsible for the Cross-Reactions to Cassava Show by People Allergic to Latex
Protein & Peptide Letters <i>Tylophora hirsuta</i> (Wall.) Extracts Ameliorate Diabetes Associated with Inflammation in Alloxan-induced Diabetic Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-Allergic and Antioxidant Activity of 5-Hydroxy-3,6,7,3’,4’- Pentamethoxy Flavone Isolated from Leaves of Vitex negundo
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pathophysiology of Chronic Obstructive Pulmonary Disease
Current Respiratory Medicine Reviews Cholesterol and Apoe: A Target for Alzheimers Disease Therapeutics
Current Drug Targets - CNS & Neurological Disorders Evaluation of Drug Transporter Interactions in Drug Discovery and Development
Combinatorial Chemistry & High Throughput Screening Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery B7-H3 Immune Checkpoint Protein in Human Cancer
Current Medicinal Chemistry Specific Biologic Therapy with Tumor Necrosis Factor Inhibitors in Patients with Inflammatory Myopathy
Current Rheumatology Reviews Ability of Goat Milk to Modulate Healthy Human Peripheral Blood Lymphomonocyte and Polymorphonuclear Cell Function: In vitro Effects and Clinical Implications
Current Pharmaceutical Design Facile Synthesis of Anticancer Drug NCX 4040 in Mild Conditions
Letters in Organic Chemistry New Insights Emerging from Recent Investigations on Human Group II Pyridoxal 5’-Phosphate Decarboxylases
Current Medicinal Chemistry